Molecular correlates of clinical response and resistance to atezolizumab in combination with bevacizumab in advanced hepatocellular carcinoma
AX Zhu, AR Abbas, MR de Galarreta, Y Guan, S Lu…�- Nature medicine, 2022 - nature.com
Atezolizumab (anti-programmed death-ligand 1 (PD-L1)) and bevacizumab (anti-vascular
endothelial growth factor (VEGF)) combination therapy has become the new standard of�…
endothelial growth factor (VEGF)) combination therapy has become the new standard of�…
Atezolizumab and bevacizumab for hepatocellular carcinoma: mechanism, pharmacokinetics and future treatment strategies
X Liu, Y Lu, S Qin�- Future oncology, 2021 - Taylor & Francis
Hepatocellular carcinoma (HCC) is a common cancer globally and a leading cause of
cancer-related deaths. Although early-stage disease may be curable by resection, liver�…
cancer-related deaths. Although early-stage disease may be curable by resection, liver�…
Safety and clinical activity of 1L atezolizumab+ bevacizumab in a phase Ib study in hepatocellular carcinoma (HCC).
S Stein, MJ Pishvaian, MS Lee, KH Lee, S Hernandez… - 2018 - ascopubs.org
4074 Background: Advanced HCC is a lethal cancer with a high unmet medical need. Single-
agent immunotherapy with PD-L1/PD-1 blockade or treatment (Tx) with anti-angiogenic�…
agent immunotherapy with PD-L1/PD-1 blockade or treatment (Tx) with anti-angiogenic�…
Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b study
MS Lee, BY Ryoo, CH Hsu, K Numata, S Stein…�- The Lancet�…, 2020 - thelancet.com
Background Dual blockade of PD-L1 and VEGF has enhanced anticancer immunity through
multiple mechanisms and augmented antitumour activity in multiple malignancies. We�…
multiple mechanisms and augmented antitumour activity in multiple malignancies. We�…
[HTML][HTML] Updated safety and clinical activity results from a phase Ib study of atezolizumab+ bevacizumab in hepatocellular carcinoma (HCC)
MJ Pishvaian, MS Lee, BY Ryoo, S Stein…�- Annals of�…, 2018 - annalsofoncology.org
Background: Agents targeting angiogenesis or PD-L1/PD-1 signalling represent 2 types of
approved treatments (tx) for HCC. In addition to its anti-angiogenic activity, bevacizumab�…
approved treatments (tx) for HCC. In addition to its anti-angiogenic activity, bevacizumab�…
Atezolizumab in advanced hepatocellular carcinoma: good things come to those who wait
A Rizzo, AD Ricci, G Brandi�- Immunotherapy, 2021 - Taylor & Francis
Advanced hepatocellular carcinoma (HCC) patients present poor prognosis. However,
recent years have seen the advent of several novel treatments in this setting, where the role�…
recent years have seen the advent of several novel treatments in this setting, where the role�…
[HTML][HTML] Scientific rationale for combined immunotherapy with PD-1/PD-L1 antibodies and VEGF inhibitors in advanced hepatocellular carcinoma
M Kudo�- Cancers, 2020 - mdpi.com
A successful phase III trial for the combination of atezolizumab and bevacizumab (the
IMbrave150 trial) in advanced hepatocellular carcinoma has recently been reported. This is�…
IMbrave150 trial) in advanced hepatocellular carcinoma has recently been reported. This is�…
Atezolizumab plus bevacizumab—a landmark in liver cancer
RK Kelley�- New England Journal of Medicine, 2020 - Mass Medical Soc
More than a decade ago, sorafenib became the first systemic therapy that conferred a
meaningful survival benefit in the treatment of advanced hepatocellular carcinoma. 1 Since�…
meaningful survival benefit in the treatment of advanced hepatocellular carcinoma. 1 Since�…
Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma
RS Finn, S Qin, M Ikeda, PR Galle…�- …�England Journal of�…, 2020 - Mass Medical Soc
Background The combination of atezolizumab and bevacizumab showed encouraging
antitumor activity and safety in a phase 1b trial involving patients with unresectable�…
antitumor activity and safety in a phase 1b trial involving patients with unresectable�…
Immunotherapies for hepatocellular carcinoma
JM Llovet, F Castet, M Heikenwalder…�- Nature reviews Clinical�…, 2022 - nature.com
Liver cancer, more specifically hepatocellular carcinoma (HCC), is the second leading
cause of cancer-related death and its incidence is increasing globally. Around 50% of�…
cause of cancer-related death and its incidence is increasing globally. Around 50% of�…
Related searches
- combination with bevacizumab clinical response
- hepatocellular carcinoma clinical activity
- hepatocellular carcinoma atezolizumab bevacizumab
- hepatocellular carcinoma treatment strategies
- hepatocellular carcinoma updated safety
- atezolizumab bevacizumab clinical activity
- atezolizumab and bevacizumab treatment strategies
- atezolizumab bevacizumab updated safety